Helixmith Co., Ltd (084990.KQ)
KRW 2770.0
(0.0%)
KRW 2770.0
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 37.36 Billion KRW | -37.31% |
| 2022 | 42.55 Billion KRW | 4.55% |
| 2021 | 40.7 Billion KRW | -11.43% |
| 2020 | 45.95 Billion KRW | 15.7% |
| 2019 | 39.71 Billion KRW | 81.09% |
| 2018 | 21.93 Billion KRW | 132.88% |
| 2017 | 9.41 Billion KRW | 17.45% |
| 2016 | 8.01 Billion KRW | 41.66% |
| 2015 | 5.66 Billion KRW | 0.0% |
| 2013 | 5.3 Billion KRW | -31.62% |
| 2012 | 7.75 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 5.08 Billion KRW | 39.1% |
| 2024 Q2 | 5.13 Billion KRW | 1.07% |
| 2023 Q4 | 3.65 Billion KRW | -37.34% |
| 2023 FY | 26.67 Billion KRW | -37.31% |
| 2023 Q1 | 10.12 Billion KRW | -13.19% |
| 2023 Q2 | 6.94 Billion KRW | -31.42% |
| 2023 Q3 | 5.83 Billion KRW | -16.01% |
| 2022 FY | 42.55 Billion KRW | 4.55% |
| 2022 Q2 | 10.58 Billion KRW | 5.22% |
| 2022 Q3 | 10.07 Billion KRW | -4.8% |
| 2022 Q1 | 10.06 Billion KRW | -19.33% |
| 2022 Q4 | 11.66 Billion KRW | 15.8% |
| 2021 Q3 | 9.79 Billion KRW | 14.83% |
| 2021 Q4 | 12.47 Billion KRW | 27.3% |
| 2021 FY | 40.7 Billion KRW | -11.43% |
| 2021 Q2 | 8.53 Billion KRW | -14.13% |
| 2021 Q1 | 9.93 Billion KRW | 787.08% |
| 2020 FY | 45.95 Billion KRW | 15.7% |
| 2020 Q1 | 58.62 Billion KRW | -39.4% |
| 2020 Q2 | 9.63 Billion KRW | -83.56% |
| 2020 Q3 | 15.41 Billion KRW | 59.92% |
| 2020 Q4 | 1.12 Billion KRW | -92.73% |
| 2019 Q2 | 13.63 Billion KRW | -14.98% |
| 2019 FY | 39.71 Billion KRW | 81.09% |
| 2019 Q1 | 16.03 Billion KRW | -14.08% |
| 2019 Q4 | 96.73 Billion KRW | 1234.14% |
| 2019 Q3 | 7.25 Billion KRW | -46.81% |
| 2018 FY | 21.93 Billion KRW | 132.88% |
| 2018 Q3 | 6.52 Billion KRW | 104.47% |
| 2018 Q4 | 18.65 Billion KRW | 185.77% |
| 2018 Q2 | 3.19 Billion KRW | 0.57% |
| 2018 Q1 | 3.17 Billion KRW | -23.54% |
| 2017 Q3 | 2.07 Billion KRW | -5.1% |
| 2017 FY | 9.41 Billion KRW | 17.45% |
| 2017 Q2 | 2.18 Billion KRW | -7.4% |
| 2017 Q1 | 2.35 Billion KRW | 0.0% |
| 2017 Q4 | 4.15 Billion KRW | 100.36% |
| 2016 FY | 8.01 Billion KRW | 41.66% |
| 2015 FY | 5.66 Billion KRW | 0.0% |
| 2014 Q1 | 1.49 Billion KRW | -51.87% |
| 2014 Q3 | 1.51 Billion KRW | 3.78% |
| 2014 Q2 | 1.46 Billion KRW | -2.21% |
| 2013 FY | 5.3 Billion KRW | -31.62% |
| 2013 Q3 | 60.4 Million KRW | -92.12% |
| 2013 Q2 | 766.13 Million KRW | -44.22% |
| 2013 Q1 | 1.37 Billion KRW | -70.24% |
| 2013 Q4 | 3.1 Billion KRW | 5038.22% |
| 2012 FY | 7.75 Billion KRW | 0.0% |
| 2012 Q4 | 4.61 Billion KRW | 654.42% |
| 2012 Q3 | 611.74 Million KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| HLB Co., Ltd. | 109.98 Billion KRW | 66.026% |
| iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -376.269% |
| BINEX Co., Ltd. | 55.67 Billion KRW | 32.884% |
| Bioneer Corporation | 204.55 Billion KRW | 81.733% |
| Anterogen.Co.,Ltd. | 7.74 Billion KRW | -382.769% |
| MEDIPOST Co., Ltd. | 65.31 Billion KRW | 42.789% |
| CrystalGenomics, Inc. | 32.36 Billion KRW | -15.438% |
| Chabiotech Co.,Ltd. | 285.93 Billion KRW | 86.932% |
| Medy-Tox Inc. | 110.88 Billion KRW | 66.301% |
| Peptron, Inc. | 16.65 Billion KRW | -124.34% |
| Amicogen, Inc. | 52.82 Billion KRW | 29.26% |
| Genexine, Inc. | 41.62 Billion KRW | 10.236% |
| HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -131.14% |
| LegoChem Biosciences, Inc. | 98.61 Billion KRW | 62.11% |
| ALTEOGEN Inc. | 40.93 Billion KRW | 8.716% |
| PharmaResearch Co., Ltd. | 89.44 Billion KRW | 58.221% |
| SillaJen, Inc. | 5.11 Billion KRW | -630.936% |
| JETEMA, Co., Ltd. | 25.66 Billion KRW | -45.6% |
| OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -6.008% |
| Genomictree Inc. | 16.26 Billion KRW | -129.742% |
| MedPacto, Inc. | 26.91 Billion KRW | -38.812% |
| D&D Pharmatech | 32.16 Billion KRW | -16.18% |
| EASY BIO,Inc. | 29.67 Billion KRW | -25.935% |
| GI Innovation, Inc. | 57.59 Billion KRW | 35.118% |